Table 1.
Demographics, sickle cell disease characteristics and morbidities.
Fig 1.
Subject flow through study.
Fig 2.
Median NKTT120 serum concentrations over time by dose cohort.
Shown are the higher dose cohorts 5 (0.1 mg/kg), 6 (0.3 mg/kg) and 7 (1.0 mg/kg).
Fig 3.
Invariant NKT cell percent of T cells over time.
(A) After NKTT120, days to iNKT cell recovery above the lower limit of quantification (LLQ) generally increases across 7 dose cohorts, (B) Dose cohorts 1–4 and 5–7 by pre-drug iNKT cell levels expressed as percent of T cells. Lower pre-drug iNKT cell level is associated with longer recovery time, especially in dose cohorts 1–4.